Relmada Therapeutics, Inc. (RLMD:NASDAQ) Annual Reports & Investor Relations Material

Overview

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company that's committed to developing an array of products to help treat central nervous system (CNS) diseases and other disorders. Its foremost product candidate is Esmethadone, a promising new chemical entity and N-methyl-D-aspartate receptor antagonist that's currently in Phase 3 clinical trials for adjunctive or standalone use in treating major depressive disorder in adults. The firm was established in 2004 and is based in Coral Gables, Florida.

Annual Reports

Frequently Asked Questions

What is Relmada Therapeutics, Inc.'s ticker?

Relmada Therapeutics, Inc.'s ticker is RLMD

What exchange is Relmada Therapeutics, Inc. traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Relmada Therapeutics, Inc.'s headquarters?

They are based in New York City, New York

How many employees does Relmada Therapeutics, Inc. have?

There are 1-10 employees working at Relmada Therapeutics, Inc.

What is Relmada Therapeutics, Inc.'s website?

It is https://www.relmada.com/

What type of sector is Relmada Therapeutics, Inc.?

Relmada Therapeutics, Inc. is in the Healthcare sector

What type of industry is Relmada Therapeutics, Inc.?

Relmada Therapeutics, Inc. is in the Drug Manufacturers - Other industry

Who are Relmada Therapeutics, Inc.'s peers and competitors?

The following five companies are Relmada Therapeutics, Inc.'s industry peers:

- Cann Global Limited

- Athenex

- Assertio

- Avadel Pharmaceuticals plc

- Amneal Pharmaceuticals